United Kingdom Genetic Disorder Drugs Research
18 comprehensive market analysis studies and research reports on the United Kingdom Genetic Disorder Drugs sector, offering an overview with historical data since 2019 and forecasts up to 2030. This includes a detailed market research of 224 companies, enriched with industry statistics, insights, and a lot more.
Healthcare
Categories
18 Healthcare Reports
Categories
Showing 18 of 18 results in Genetic Disorder Drugs
Duchenne Muscular Dystrophy Treatment Market
CAGR: 19.08%
Study Period: 2019 - 2030
Country Covered: United Kingdom
Major Players:NIPPON SHINYAKU CO., LTD. (NS Pharma Inc.), ITALFARMACO S.p.A., PTC Therapeutics, Santhera Pharmaceuticals, Sarepta Therapeutics
Hereditary Angioedema Therapeutics Market
CAGR: 16.90%
Study Period: 2019 - 2030
Country Covered: United Kingdom
Major Players:Takeda Pharmaceuticals, CSL Behring, Pharming Group NV, BioCryst Pharmaceuticals, KalVista Pharmaceuticals
Monogenetic Disease Therapy Market
CAGR: 10.80%
Study Period: 2020 - 2030
Country Covered: United Kingdom
Major Players:Bayer, Novartis, Pfizer, Sanofi, Bluebird Bio
Vitiligo Treatment Market
CAGR: 6.14%
Study Period: 2019 - 2030
Country Covered: United Kingdom
Major Players:Abbvie, Pfizer, Incyte, STRATA Skin Sciences Inc., Merck
Transthyretin Amyloidosis Treatment Market
CAGR: 15.40%
Study Period: 2019 - 2030
Country Covered: United Kingdom
Major Players:Pfizer, Alnylam Pharmaceuticals, Intellia Therapeutics, Inc., AstraZeneca, BridgeBio Pharma Inc
Fabry Disease Treatment Market
CAGR: 7.74%
Study Period: 2019 - 2030
Country Covered: United Kingdom
Major Players:Sanofi, Takeda Pharmaceuticals, Amicus Therapeutics, ISU ABXIS, JCR Pharmaceuticals
DNA Repair Drugs Market
CAGR: 13.20%
Study Period: 2019 - 2030
Country Covered: United Kingdom
Major Players:AstraZeneca, GlaxoSmithKline, Merck, Pfizer, Valerio Therapeutics
Huntington's Disease Treatment Market
CAGR: 8.23%
Study Period: 2019 - 2030
Country Covered: United Kingdom
Major Players:Pfizer, Alnylam Pharmaceuticals, Teva Pharmaceutical Industries, Neurocrine Biosciences, Ionis Pharmaceuticals
Sickle Cell Treatment Market
CAGR: 14.98%
Study Period: 2019 - 2030
Country Covered: United Kingdom
Major Players:Novartis, Sanofi, Pfizer, Vertex Pharmaceuticals Inc., CRISPR Therapeutics AG
Pompe Disease Market
CAGR: 7.32%
Study Period: 2019 - 2030
Country Covered: United Kingdom
Major Players:Amicus Therapeutics, Sanofi, Exerkine Corporation, Genethon, Maze Therapeutics, Inc.
Hunter Syndrome Treatment Market
CAGR: 5.30%
Study Period: 2021 - 2030
Country Covered: United Kingdom
Major Players:REGENXBIO, Clinigen Group, JCR Pharmaceuticals, ArmaGen, Takeda Pharmaceuticals
NTRK Fusion Gene Positive Advanced Solid Tumor Market
CAGR: 5.41%
Study Period: 2019 - 2030
Country Covered: United Kingdom
Major Players:Bayer, Empire Genomics, Roche, NeoGenomics Laboratories, OncoDNA S.A.
Cystic Fibrosis Therapeutics Market
CAGR: 11.86%
Study Period: 2019 - 2030
Country Covered: United Kingdom
Major Players:Abbvie, Gilead Sciences, Vertex Pharmaceuticals Inc., Alaxia SAS, Mylan NV (Viatris)
Hemoglobinopathies Treatment Market
CAGR: 7.98%
Study Period: 2019 - 2030
Country Covered: United Kingdom
Major Players:Sanofi, Novartis, Pfizer, bluebird bio, CSL Behring
Thalassemia Treatment Market
CAGR: 3.76%
Study Period: 2019 - 2030
Country Covered: United Kingdom
Major Players:Bluebird Bio, Novartis, ApoPharma, Bellicum Pharmaceuticals, Pfizer
Global Rare Hemophilia Factors Market
CAGR: 4.3%
Study Period: 2019 - 2030
Country Covered: United Kingdom
Major Players:Bayer, Pfizer, Takeda Pharmaceuticals, Sanofi, Novo Nordisk
Von Willebrand Disease Treatment Market
CAGR: 6.5%
Study Period: 2019 - 2030
Country Covered: United Kingdom
Major Players:CSL Behring, Grifols, Octapharma, Bio Products Laboratory, Takeda (Shire)
Hemophilia Market
CAGR: 5.74%
Study Period: 2019 - 2030
Country Covered: United Kingdom
Major Players:Biomarin Pharmaceutical, CSL Behring, Roche, Novo Nordisk, Pfizer
Yay! You have seen it all
CONTACT US
When decisions matter, industry leaders turn to our analysts. Let’s talk.
